Treats relapsing forms of multiple sclerosis (MS). ANDA 209663, held by Glenmark Speclt. Teriflunomide.
As of Nov 16, 2026, ANDA 209663 (Teriflunomide), held by Glenmark Speclt, was first approved by FDA on Nov 15, 2018, with 5 approved supplements and 0 published complete response letters.
Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 15, 2018 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Rx |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Rx |
| Jan 5, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 5, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 7, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 13, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 29, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 15, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters